USPTO Examiner BUTTICE AUDREY L - Art Unit 1647

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18606648PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024February 2025Allow1100NoNo
18599838PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024November 2024Allow800YesNo
18599860PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024January 2025Allow1000NoNo
18599888PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024January 2025Allow1000NoNo
18599849PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024December 2024Allow900NoNo
18599924PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSMarch 2024January 2025Allow1100NoNo
18585158PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSFebruary 2024October 2024Allow800YesNo
18425844ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATESJanuary 2024June 2025Allow1620NoNo
18417063COMPOSITIONS AND METHODS FOR CANCER THERAPYJanuary 2024December 2024Abandon1110NoNo
18486445D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOFOctober 2023April 2025Allow1820YesNo
18475958Humanized Anti-GDNF family alpha-receptor 4 (GRF-alpha-4) Antibodies and Chimeric Antigen Receptors (CARs)September 2023December 2024Allow1510YesNo
18324425T CELL RECEPTORSMay 2023February 2024Allow910NoNo
18180704ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOFMarch 2023May 2025Abandon2620YesNo
18171208HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCERFebruary 2023April 2025Abandon2620NoNo
18169240COMBINATION THERAPY FOR TREATING OR PREVENTING CANCERFebruary 2023October 2024Abandon2010NoNo
18148903FORMULATIONS FOR PROMOTING HYDRATION AND METHODS OF USE THEREOFDecember 2022March 2025Allow2640YesNo
18147879PD1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AS AN IMMUNOTHERAPYDecember 2022October 2024Abandon2110NoNo
18067672METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPYDecember 2022July 2024Allow1910YesNo
18076997USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERSDecember 2022January 2024Allow1420NoNo
18075648ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF FOR SPECIFICALLY RECOGNIZING B CELL MALIGNANCY, CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME AND USE THEREOFDecember 2022June 2024Allow1810NoNo
18055096D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOFNovember 2022September 2023Allow1010YesNo
18049736COMPOSITIONS AND METHODS FOR CANCER THERAPYOctober 2022February 2024Allow1621YesNo
18047327ANTI-HER2 NANOBODY AND CODING SEQUENCE AND USE THEREOFOctober 2022May 2024Allow1910YesNo
17816540CD123-Binding Polypeptides and Uses ThereofAugust 2022October 2023Allow1510NoNo
17767831Compositions and Methods for Targeting CD13 and TIM-3 with CAR T Cells to Treat Acute Myeloid LeukemiaApril 2022April 2025Allow3620NoNo
17673602Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint InhibitorsFebruary 2022November 2024Abandon3320NoNo
17576866PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERSJanuary 2022November 2023Allow2201YesNo
17559329METHODS AND DELIVERY OF ALLOGENEIC CELL PRODUCTSDecember 2021December 2023Abandon2410NoNo
17559500CANCER TREATMENT USING CD38 INHIBITOR AND/OR LENALIDOMIDE AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTORDecember 2021February 2024Abandon2510NoNo
17552300T CELL RECEPTORSDecember 2021April 2022Allow400NoNo
17537687CAR T-CELL ADJUVANT THERAPIESNovember 2021July 2024Abandon3220NoNo
17522443CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATIONNovember 2021August 2024Allow3330YesYes
17522623ANTIBODY DRUG CONJUGATESNovember 2021March 2023Abandon1600NoNo
17488685ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USESeptember 2021March 2023Allow1810NoNo
17488852ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USESeptember 2021May 2023Allow2010YesNo
17433692COMBINATION THERAPIESAugust 2021March 2025Abandon4310NoNo
17433206CHIMERIC PROTEIN, METHOD OF PRODUCTION AND USE THEREOF, AND ALSO A NUCLEIC ACID MOLECULE, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, COMPOSITION FOR THE DIAGNOSIS OF LEISHMANIASIS, KIT FOR THE DIAGNOSIS OF LEISHMANIASIS AND METHOD OF DIAGNOSIS OF LEISHMANIASIS IN VITROAugust 2021February 2025Allow4210YesNo
17433012USE OF NATRIURETIC PEPTIDES TO ASSESS AND TREAT ACUTE KIDNEY INJURYAugust 2021April 2025Abandon4410NoNo
17427447NOVEL ANTI-PD-L1 ANTIBODY AND USES THEREOFJuly 2021November 2024Allow4010YesNo
17426548CHIMERIC ANTIGEN RECEPTOR AND USE THEREOFJuly 2021June 2025Allow4720NoNo
17311148IMMUNOSUPPRESIVE AGENTJune 2021October 2024Allow4010YesNo
17338767COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERSJune 2021January 2025Allow4330YesNo
17298287TREATMENT OF ACUTE GVHD USING DONOR- SPECIFIC ANTI-HLA ANTIBODIESMay 2021April 2025Abandon4620NoNo
17331832THERAPEUTIC COMPOSITIONS AND RELATED METHODSMay 2021December 2024Abandon4340NoNo
17291719Treatment for Giant Cell ArteritisMay 2021October 2024Abandon4210NoNo
17228871PSMA AND STEAP1 VACCINES AND THEIR USESApril 2021February 2025Abandon4740YesNo
17177890METHODS AND AGENTS FOR TREATING ORGAN INJURY AND TRANSPLANT REJECTIONFebruary 2021December 2023Abandon3420YesNo
17166759METHOD OF TREATING CANCER BY TARGETING MYELOID-DERIVED SUPPRESSOR CELLSFebruary 2021October 2023Abandon3240YesNo
17155251TRANSDERMAL SYSTEM FOR SYNERGISTIC IMMUNE-CHEMOTHERAPY USING MICRONEEDLES AND METHOD OF TREATMENT THEREOFJanuary 2021May 2025Abandon5230YesNo
17144834COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCERJanuary 2021September 2023Allow3311YesNo
17092386VACCINATION WITH CANCER NEOANTIGENSNovember 2020July 2024Abandon4510NoNo
17089594USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORSNovember 2020January 2025Abandon5140YesNo
17045406STABLE FORMULATIONS OF THERAPEUTIC ANTIBODYOctober 2020June 2025Allow5650YesNo
17037203Humanized Anti-GDNF family alpha-receptor 4 (GRF-alpha-4) Antibodies and Chimeric Antigen Receptors (CARs)September 2020June 2023Allow3320YesNo
17042838HUMANIZED ANTI-PROSTATE -SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATESSeptember 2020May 2023Allow3210YesNo
17041917TARGET FOR DRUG TREATMENT OF TUMOR METASTASIS AND USE THEREOFSeptember 2020April 2025Abandon5530NoNo
17025991ANTIGEN BINDING MOLECULES FOR SMALL CELL LUNG CANCERSeptember 2020February 2025Allow5340YesNo
17019059ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USESeptember 2020June 2021Allow910NoNo
17019091ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USESeptember 2020June 2021Allow910NoNo
16934745HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCERJuly 2020June 2023Abandon3510NoNo
16932048COMBINATION THERAPY FOR TREATING OR PREVENTING CANCERJuly 2020April 2023Abandon3310NoNo
16927661METHOD TO ISOLATE TCR GENESJuly 2020May 2025Abandon5831NoNo
16961133METHODS AND COMBINATION THERAPY TO TREAT CANCERJuly 2020April 2023Abandon3320NoNo
16961200EPIGENETIC MODIFIERS FOR USE IN CELLULAR IMMUNOTHERAPYJuly 2020September 2023Abandon3830YesNo
16957647NOVEL SCFV AMINO ACID SEQUENCE, CHIMERIC ANTIGEN RECEPTOR CONTAINING SAME AND APPLICATION THEREOFJune 2020December 2022Allow3010NoNo
16771027NKG2D DARIC RECEPTORSJune 2020December 2023Abandon4221NoNo
16768412Antibody Or Antigen Binding Fragment Thereof For Specifically Recognizing B Cell Malignancy, Chimeric Antigen Receptor Comprising Same And Use ThereofMay 2020November 2022Allow2910NoNo
16767487COMPOSITIONS AND METHODS FOR TREATING CANCERMay 2020September 2023Abandon4030YesNo
16766224ILDR2 ANTAGONISTS AND COMBINATIONS THEREOFMay 2020January 2023Allow3220NoNo
16766128POLYPEPTIDEMay 2020January 2023Allow3110NoNo
16877907USE OF IGF-1 IN THE PREPARATION OF MEDICAMENTS FOR PREVENTING AND/OR TREATING LIVER TUMORSMay 2020June 2022Abandon2510NoNo
16764248Methods of Treating GlioblastomaMay 2020October 2023Abandon4120YesNo
15931789MEDICAMENT FOR CANCER TREATMENTMay 2020June 2025Abandon6080YesNo
16763539CELLMay 2020January 2023Abandon3210NoNo
16868927Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses ThereofMay 2020October 2024Abandon5330NoNo
16761784Inhibition of CTLA-4 and/or PD-1 For Regulation of T CellsMay 2020October 2024Abandon5360NoNo
16864478CD123-Binding Polypeptides and Uses ThereofMay 2020May 2022Allow2410NoNo
16760179ANTI-CD5L ANTIBODY AND USES THEREOFApril 2020March 2022Allow2310NoNo
16760382METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPYApril 2020September 2022Allow2920NoNo
16858509AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOFApril 2020October 2023Abandon4121NoNo
16758474METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPYApril 2020February 2023Allow3410NoNo
16758124ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOFApril 2020November 2022Allow3110NoNo
16757156ANTI-VISTA ANTIBODY AND USE THEREOFApril 2020March 2022Allow2311NoNo
16851725REPROGRAMMING OF POLYMORPHONUCLEAR LEUKOCYTESApril 2020February 2023Abandon3410NoNo
16652230METHOD FOR TREATING GLIOBLASTOMAMarch 2020June 2023Abandon3920YesNo
16652011PRODUCTION METHOD FOR IPS CELL-DERIVED POPULATION OF GENETICALLY DIVERSE T CELLSMarch 2020October 2024Abandon5450NoNo
16832440DOSING OF A BISPECIFIC ANTIBODY THAT BINDS PD1 AND CTLA4March 2020June 2024Abandon5160NoNo
16832170SEMAPHORIN-4D ANTAGONISTS FOR USE IN CANCER THERAPYMarch 2020January 2025Abandon5861NoNo
16650884PD1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AS AN IMMUNOTHERAPYMarch 2020May 2022Allow2610NoNo
16649914METHOD FOR TREATING MYELOID LEUKEMIAMarch 2020July 2023Abandon4020NoNo
16649763ANTI IGF, ANTI PD-1, ANTI-CANCER COMBINATION THERAPYMarch 2020June 2022Abandon2710NoNo
16826405COMPOUNDS AND CONJUGATES THEREOFMarch 2020February 2024Abandon4721YesNo
16649157NOVEL ANTI-CD19 ANTIBODIESMarch 2020July 2022Allow2810NoNo
16823987CD28 T CELL CULTURES, COMPOSITIONS, AND METHODS OF USING THEREOFMarch 2020February 2025Abandon5921NoNo
16648033ANTI-PD-L1 ANTIBODY AND USES THEREOFMarch 2020July 2022Allow2811NoNo
16645247GENETICALLY ENGINEERED T CELL AND APPLICATION THEREOFMarch 2020June 2023Abandon3911NoNo
16645064IMMUNOCONJUGATES COMPRISING SIGNAL REGULATORY PROTEIN ALPHAMarch 2020August 2022Allow2911NoNo
16791217Combination Therapy For Treatment Of B-Cell MalignanciesFebruary 2020October 2024Abandon5651NoNo
16637972Reprogramming of CD8 T Cells with CXCL12 Signaling InhibitorsFebruary 2020November 2022Abandon3320NoNo
16637600TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUSFebruary 2020June 2022Abandon2801NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BUTTICE, AUDREY L.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
0.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BUTTICE, AUDREY L - Prosecution Strategy Guide

Executive Summary

Examiner BUTTICE, AUDREY L works in Art Unit 1647 and has examined 107 patent applications in our dataset. With an allowance rate of 44.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner BUTTICE, AUDREY L's allowance rate of 44.9% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BUTTICE, AUDREY L receive 2.07 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BUTTICE, AUDREY L is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +18.2% benefit to allowance rate for applications examined by BUTTICE, AUDREY L. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.7% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.